IMAB
I-Mab
NASDAQ · Healthcare · Biotechnology · US
$2.88
−0.69%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +95.8%
- EBIT
- +93.2%
- EPS
- +91.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -8.5%
- EBIT
- +26.6%
- Net income
- +88.9%
- EPS
- +74.7%
- Free cash flow
- +27.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025